Please assess the completion status of the following clinical trial:

Trial Title: HD17 for Intermediate Stage Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hodgkin Lymphoma~* CS I, II with risk factor (stage IIB with risk factor 1 or 2 are not included)~* large mediastinal mass (\>1/3 of maximum transverse thorax diameter)~* extranodal involvement~* elevated ESR~* 3 or more involved nodal areas~* written informed consent~Exclusion Criteria:~* Leucocytes \<3000/µl~* Platelets \< 100000/µl~* Hodgkin Lymphoma as composite lymphoma~* Activity Index (WHO) \>2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): 2 cycles BEACOPPescalated plus 2 cycles ABVD followed by 30Gy IF-RT irrespective of FDG-PET results after chemotherapy
- Arm B (Type: EXPERIMENTAL): 2 cycles BEACOPPescalated plus 2 cycles ABVD followed by 30Gy IN-RT if FDG-PET is positive after chemotherapy; 2 cycles BEACOPPescalated plus 2 cycles ABVD and treatment stop if FDG-PET is negative after chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).